Benefits of CRISPR-edited gene therapy for patients with blood disorders

Sickle cell disease
Credit: National Institutes of Health

In a late-breaking abstract presented at the European Hematology Association (EHA) Congress, a group of researchers that includes Children's Hospital of Philadelphia (CHOP) presented new data on an investigational therapy for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). The one-time treatment, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, showed continued benefits at up to three years after administration, with a safety profile as expected for autologous transplant and potentially much safer than allogeneic transplant (from a donor).

"These data provide further evidence that this treatment has the potential to be transformational for patients with and ," said senior abstract author and immunotherapy pioneer Stephan A. Grupp, MD, Ph.D., Section Chief of the Cellular Therapy and Transplant Section and Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy at CHOP. "Although we must continue to investigate the durability of these results, I am excited about the current data."

The abstract provides new data from two clinical trials on exa-cel (exagamglogene autotemcel), formerly known as CTX001, a one-time treatment that utilizes CRISPR gene editing to boost the production of to correct the defective gene for hemoglobin associated with both diseases.

The researchers presented results from 75 patients: 44 with TDT and 31 with SCD. Of the 44 patients with TDT, 42 were transfusion-free at follow-up, which ranged from 1.2 to 37.2 months after exa-cel infusion. All 31 patients with SCD were free of vaso-occlusive crises at follow-up, which ranged from 2 to 32.3 months.

The safety was generally consistent with myeloablative conditioning with busulfan and autologous stem cell transplant. Two of the 44 patients with TDT had serious adverse events (SAEs) potentially related to exa-cel, while none of the SCD patients had SAEs considered to be related to the cell therapy.

More information: Franco Locatelli et al, Efficacy And Safety Of A Single Dose Of CTX001 For Transfusion-Dependent Beta-Thalassemia and Severe Sickle Cell Disease, Abstract LB2367, European Hematology Association (EHA) Congress 2022

Provided by Children’s Hospital of Philadelphia
Citation: Benefits of CRISPR-edited gene therapy for patients with blood disorders (2022, June 14) retrieved 16 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Positive preliminary data on CRISPR treatment for blood diseases


Feedback to editors